Nuevocor

Nuevocor is a pioneering biotechnology research company focused on developing innovative genetic medicines. Specializing in therapies for previously untreatable genetic cardiomyopathies, Nuevocor leverages its proprietary PrOSIA mechanobiology platform to create groundbreaking solutions. With a commitment to advancing cardiac care, Nuevocor is dedicated to transforming the lives of patients worldwide.

Nuevocor is strategically located with offices in both Singapore and the United States, allowing for global collaboration and access to diverse research environments. The primary address is in Singapore, SG, with additional operations in Philadelphia, US. This international presence enables Nuevocor to stay at the forefront of biotechnology advancements and address critical healthcare needs on a global scale.

Nuevocor is poised to make significant contributions to the field of genetic medicine. The company’s unwavering focus on innovation and patient well-being drives its mission to develop effective treatments for complex cardiac conditions. We invite the management team at Nuevocor to further enrich this profile with a customized company showcase and detailed product listings, enhancing visibility and commercial opportunities on our platform.